34.37
price up icon3.34%   1.11
after-market Handel nachbörslich: 34.37
loading
Schlusskurs vom Vortag:
$33.26
Offen:
$33.11
24-Stunden-Volumen:
603.49K
Relative Volume:
1.01
Marktkapitalisierung:
$2.00B
Einnahmen:
$32.87M
Nettoeinkommen (Verlust:
$674.31M
KGV:
3.0255
EPS:
11.36
Netto-Cashflow:
$-330.11M
1W Leistung:
+2.84%
1M Leistung:
+7.11%
6M Leistung:
+4.60%
1J Leistung:
-20.77%
1-Tages-Spanne:
Value
$32.87
$35.03
1-Wochen-Bereich:
Value
$32.53
$35.03
52-Wochen-Spanne:
Value
$23.41
$62.58

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name
Firmenname
Agios Pharmaceuticals Inc
Name
Telefon
617-649-8600
Name
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Name
Mitarbeiter
488
Name
Twitter
@AgiosPharma
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
AGIO's Discussions on Twitter

Vergleichen Sie AGIO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
AGIO
Agios Pharmaceuticals Inc
34.37 2.00B 32.87M 674.31M -330.11M 11.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-24 Eingeleitet H.C. Wainwright Buy
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-10-10 Fortgesetzt Raymond James Outperform
2024-09-27 Herabstufung Leerink Partners Outperform → Market Perform
2024-02-08 Eingeleitet Cantor Fitzgerald Overweight
2023-02-03 Eingeleitet Piper Sandler Overweight
2022-11-17 Hochstufung Goldman Sell → Neutral
2022-07-27 Hochstufung SVB Leerink Mkt Perform → Outperform
2021-12-03 Eingeleitet BofA Securities Buy
2021-07-30 Herabstufung Goldman Neutral → Sell
2021-07-01 Eingeleitet Raymond James Mkt Perform
2021-06-10 Eingeleitet H.C. Wainwright Buy
2021-03-01 Herabstufung JP Morgan Overweight → Neutral
2021-03-01 Hochstufung SVB Leerink Mkt Perform → Outperform
2021-02-26 Herabstufung SVB Leerink Outperform → Mkt Perform
2020-10-22 Hochstufung Barclays Equal Weight → Overweight
2020-03-04 Eingeleitet Barclays Equal Weight
2019-11-26 Eingeleitet Cantor Fitzgerald Overweight
2019-09-23 Hochstufung Guggenheim Neutral → Buy
2019-05-23 Fortgesetzt Goldman Neutral
2019-02-15 Hochstufung SVB Leerink Mkt Perform → Outperform
2018-09-25 Eingeleitet Leerink Partners Mkt Perform
2018-05-23 Eingeleitet Citigroup Buy
2018-04-11 Bestätigt Credit Suisse Outperform
2018-02-15 Bestätigt Needham Buy
2018-02-15 Bestätigt SunTrust Buy
2017-09-15 Eingeleitet RBC Capital Mkts Outperform
2017-08-10 Bestätigt Needham Buy
2017-08-08 Bestätigt SunTrust Buy
2017-08-02 Hochstufung Leerink Partners Mkt Perform → Outperform
2017-06-26 Herabstufung Janney Buy → Neutral
2017-01-17 Hochstufung Oppenheimer Perform → Outperform
2016-10-24 Eingeleitet Needham Buy
2016-06-13 Hochstufung JP Morgan Neutral → Overweight
2016-05-18 Bestätigt SunTrust Buy
Alle ansehen

Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten

pulisher
Jun 18, 2025

Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s Market Potential - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Agios Pharma Increases Shares in Stock Incentive Plan - TipRanks

Jun 18, 2025
pulisher
Jun 17, 2025

H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Agios' PYRUKYND Faces FDA Review In SeptemberExpansion Opportunity Ahead? - RTTNews

Jun 17, 2025
pulisher
Jun 16, 2025

10 Best NASDAQ Stocks Under $50 to Buy - Insider Monkey

Jun 16, 2025
pulisher
Jun 16, 2025

TD Cowen reiterates buy rating on Agios stock ahead of key trial data - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Agios Pharmaceuticals Sees Shift in Fund Positioning Russell 1000 - Kalkine Media

Jun 16, 2025
pulisher
Jun 11, 2025

10 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

Agios Pharmaceuticals: A More Compelling Valuation (NASDAQ:AGIO) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Avanzanite annuncia la partnership paneuropea con Agios per lanciare mitapivat nelle malattie ematologiche rare - standard-journal.com

Jun 11, 2025
pulisher
Jun 11, 2025

Avanzanite annonce un partenariat paneuropéen avec Agios pour le lancement de PYRUKYND® dans les maladies rares du sang - Eagle-Tribune

Jun 11, 2025
pulisher
Jun 11, 2025

Avanzanite gibt europaweite Partnerschaft mit Agios zur Einführung von PYRUKYND® bei seltenen Blutgerinnungsstörungen bekannt - standard-journal.com

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Predicts AGIO FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Agios Pharma stock target cut to $56 by H.C. Wainwright - Investing.com Canada

Jun 10, 2025
pulisher
Jun 09, 2025

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders - afp.com

Jun 09, 2025
pulisher
Jun 09, 2025

Agios Pharmaceuticals (AGIO) Target Price Revised Amid New Europ - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Agios Pharmaceuticals (AGIO) Target Price Revised Amid New European Deal | AGIO Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Agios at Goldman Sachs Conference: Strategic Growth in Rare Diseases By Investing.com - Investing.com Canada

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : Agios Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Agios stock rises on European distribution deal By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Agios stock rises on European distribution deal - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders | AGIO Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

California State Teachers Retirement System Trims Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World

Jun 09, 2025
pulisher
Jun 09, 2025

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND in Rare Blood Disorders - Business Wire

Jun 09, 2025
pulisher
Jun 07, 2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.50 Average Target Price from Analysts - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Holdings Lowered by Millennium Management LLC - Defense World

Jun 07, 2025
pulisher
Jun 01, 2025

Nuveen Asset Management LLC Cuts Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World

Jun 01, 2025
pulisher
Jun 01, 2025

Ameriprise Financial Inc. Sells 34,140 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

When the Price of (AGIO) Talks, People Listen - news.stocktradersdaily.com

May 31, 2025
pulisher
May 28, 2025

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 | AGIO Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 - The Manila Times

May 28, 2025
pulisher
May 28, 2025

Agios Pharmaceuticals Showcases Rare Disease Breakthroughs at Goldman Sachs Healthcare Conference - Stock Titan

May 28, 2025
pulisher
May 27, 2025

BNP Paribas Financial Markets Sells 2,242 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World

May 27, 2025
pulisher
May 26, 2025

What is Zacks Research’s Estimate for AGIO Q2 Earnings? - Defense World

May 26, 2025
pulisher
May 22, 2025

Agios Pharmaceuticals’ SWOT analysis: promising drug pipeline drives stock outlook By Investing.com - Investing.com South Africa

May 22, 2025
pulisher
May 22, 2025

Agios Pharmaceuticals’ SWOT analysis: promising drug pipeline drives stock outlook - Investing.com Canada

May 22, 2025
pulisher
May 22, 2025

Bank of America Corp DE Raises Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World

May 22, 2025
pulisher
May 20, 2025

Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded to Sell Rating by StockNews.com - Defense World

May 20, 2025
pulisher
May 19, 2025

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates - MSN

May 19, 2025
pulisher
May 17, 2025

Analysts Update Their Estimates For Agios Pharmaceuticals Inc - Stocksregister

May 17, 2025
pulisher
May 17, 2025

Agios pharmaceuticals outlines key catalysts for PYRUKYND pipeline in 2025 - MSN

May 17, 2025
pulisher
May 15, 2025

Agios Pharma (AGIO) Gets a Buy from Bank of America Securities - The Globe and Mail

May 15, 2025
pulisher
May 15, 2025

Beta thalassemia Market: Epidemiology, Therapies, Companies, - openPR.com

May 15, 2025
pulisher
May 15, 2025

Sickle cell disease Market: Epidemiology, Therapies, - openPR.com

May 15, 2025
pulisher
May 14, 2025

Agios Pharmaceuticals at Bank of America 2025 Healthcare Conference: Strategic Pipeline Advances - Investing.com Canada

May 14, 2025
pulisher
May 14, 2025

Agios to Highlight Pyruvate Kinase Activation Portfolio with New - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Agios Pharmaceuticals (AGIO) Highlights Promising Data at EHA 20 - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Agios Pharmaceuticals (AGIO) Highlights Promising Data at EHA 2025 | AGIO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress - The Manila Times

May 14, 2025
pulisher
May 14, 2025

New Phase 3 Trial Data: Agios Blood Disorder Treatment Shows Promise in Children and Adults with Rare Diseases - Stock Titan

May 14, 2025
pulisher
May 14, 2025

Northern Trust Corp Purchases 5,372 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World

May 14, 2025

Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Agios Pharmaceuticals Inc-Aktie (AGIO) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Burns James William
Chief Legal Officer
Jun 24 '25
Sale
33.54
2,799
93,878
28,650
Gheuens Sarah
Chief Medical Officer
Jun 24 '25
Option Exercise
0.00
6,000
0
59,897
Gheuens Sarah
Chief Medical Officer
Jun 24 '25
Sale
33.54
2,909
97,568
56,988
Jones Cecilia
Chief Financial Officer
Jun 24 '25
Option Exercise
0.00
6,000
0
31,829
Jones Cecilia
Chief Financial Officer
Jun 24 '25
Sale
33.54
1,780
59,701
30,049
Milanova Tsveta
Chief Commercial Officer
Jun 24 '25
Option Exercise
0.00
6,000
0
28,892
Milanova Tsveta
Chief Commercial Officer
Jun 24 '25
Sale
33.54
2,770
92,906
26,122
Goff Brian
Chief Executive Officer
Jun 24 '25
Option Exercise
0.00
38,277
0
118,151
Goff Brian
Chief Executive Officer
Jun 24 '25
Sale
33.54
18,700
627,198
105,401
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Kapitalisierung:     |  Volumen (24h):